Sanofi (NASDAQ:SNY) Cut to “Hold” at StockNews.com
From MarketBeat:
create short ,engaging summaries of the news. Limit summaries to 45 words per paragraph. Ensure clarity and engagement, Include all facts, statistics and figures. Arrange summaries sequentially or by relevance in easy to read paragraph format. Verify accuracy and state only facts, ignore any promotional or marketing of services in the article:
Sanofi (NASDAQ:SNY – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
SNY has been the topic of several other research reports. JPMorgan Chase & Co. downgraded Sanofi from an “overweight” rating to a “neutral” rating in a research report on Tuesday, December 5th. Stifel Nicolaus downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $60.00.
Get Our Latest Stock Analysis on Sanofi
Sanofi Stock Performance
NASDAQ:SNY opened at $49.75 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82. The stock’s 50 day simple moving average is $47.48 and its two-hundred day simple moving average is $51.30. The company has a market cap of $125.85 billion, a price-to-earnings ratio of 15.60, a PEG ratio of 2.19 and a beta of 0.59.
Sanofi (NASDAQ:SNY – Get Free Report) last released its earnings results on Friday, October 27th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.02. The firm had revenue of $13.02 billion for the quarter, compared to the consensus estimate of $13.61 billion. Sanofi had a return on equity of 27.55% and a net margin of 17.34%. As a group, equities analysts anticipate that Sanofi will post 4.4 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. boosted its position in Sanofi by 25.5% during the third quarter. B. Riley Wealth Advisors Inc. now owns 20,925 shares of the company’s stock worth $1,122,000 after purchasing an additional 4,257 shares in the last quarter. American Century Companies Inc. boosted its position in Sanofi by 1.0% during the third quarter. American Century Companies Inc. now owns 1,472,190 shares of the company’s stock worth $78,968,000 after purchasing an additional 15,154 shares in the last quarter. EP Wealth Advisors LLC boosted its position in Sanofi by 13.4% during the third quarter. EP Wealth Advisors LLC now owns 4,780 shares of the company’s stock worth $256,000 after purchasing an additional 563 shares in the last quarter. Creative Planning boosted its position in Sanofi by 30.4% during the third quarter. Creative Planning now owns 181,652 shares of the company’s stock worth $9,744,000 after purchasing an additional 42,358 shares in the last quarter. Finally, Belpointe Asset Management LLC boosted its position in Sanofi by 70.2% during the third quarter. Belpointe Asset Management LLC now owns 7,298 shares of the company’s stock worth $392,000 after purchasing an additional 3,009 shares in the last quarter. 10.06% of the stock is owned by institutional investors and hedge funds.
Sanofi Company Profile (Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
NASDAQ: SNY’ width=”600″ height=”385″ />
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanofi, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sanofi wasn’t on the list.
While Sanofi currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Read more: Sanofi (NASDAQ:SNY) Cut to “Hold” at StockNews.com